In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...

SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial

publication date: Aug 28, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Beijing SL Pharmaceutical Co. Ltd. received SFDA approval to begin producing a hepatitis drug and a second SFDA authorization to begin clinical trials of drug for male infertility. Adefovir dipivoxil, the drug newly approved for marketing, is aimed at hepatitis B. SL Pharma’s male infertility product is thought to be modafinil, the stimulant drug that is marketed as Provigil by Cephalon. More details...

Stock Symbols: (SZSE: 002038) (NSDQ: CEPH)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners